{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:47:50Z","timestamp":1782103670602,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"DST PURSE"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00210-026-04984-9","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:43:04Z","timestamp":1769229784000},"page":"9805-9815","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abaloparatide-Zoledronate combination protects against 4-vinylcyclohexene diepoxide\u2013induced postmenopausal osteoporosis in mice: an osteoanabolic-antiresorptive approach"],"prefix":"10.1007","volume":"399","author":[{"given":"Tabasum","family":"Ara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreshta","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil Ahmad","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-9191","authenticated-orcid":false,"given":"Divya","family":"Vohora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"4984_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073655","author":"T Abe","year":"2024","unstructured":"Abe T, Miyazaki M, Sako N, Kanezaki S, Tsubouchi Y, Kaku N (2024) Optimal intermittent administration interval of abaloparatide for bone morphogenetic protein-induced bone formation in a rat spinal fusion model. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25073655","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4984_CR2","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s00198-016-3701-9","volume":"27","author":"MW Aref","year":"2016","unstructured":"Aref MW, McNerny EM, Brown D, Jepsen KJ, Allen MR (2016) Zoledronate treatment has different effects in mouse strains with contrasting baseline bone mechanical phenotypes. Osteoporos Int 27(12):3637\u20133643","journal-title":"Osteoporos Int"},{"key":"4984_CR3","doi-asserted-by":"publisher","first-page":"100291","DOI":"10.1016\/j.bonr.2020.100291","volume":"13","author":"H Arlt","year":"2020","unstructured":"Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, Lanske B, Besschetnova T (2020) Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice. Bone Rep 13:100291","journal-title":"Bone Rep"},{"key":"4984_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bcp.2019.05.024","volume":"166","author":"S Bhattacharyya","year":"2019","unstructured":"Bhattacharyya S, Pal S, Chattopadhyay N (2019) Abaloparatide, the second generation osteoanabolic drug: molecular mechanisms underlying its advantages over the first-in-class teriparatide. Biochem Pharmacol 166:185\u2013191","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"4984_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11914-008-0005-9","volume":"6","author":"JP Bilezikian","year":"2008","unstructured":"Bilezikian JP (2008) Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep 6(1):24\u201330","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"4984_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B, Sim\u00f5es ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93(3):852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"4984_CR7","doi-asserted-by":"publisher","unstructured":"Brooks HL, Pollow DP, Hoyer PB (2016) The VCD Mouse Model of Menopause and Perimenopause for the Study of Sex Differences in Cardiovascular Disease and the Metabolic Syndrome. Physiology (Bethesda) 31(4):250\u2013257. https:\/\/doi.org\/10.1152\/physiol.00057.2014","DOI":"10.1152\/physiol.00057.2014"},{"key":"4984_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/bonekey.2014.13","volume":"3","author":"F Cosman","year":"2014","unstructured":"Cosman F (2014) Combination therapy for osteoporosis: a reappraisal. BoneKEy Rep 3:518","journal-title":"BoneKEy Rep"},{"issue":"3","key":"4984_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C, Miller PD, Gua\u00f1abens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J Bone Miner Res 26(3):503\u2013511","journal-title":"J Bone Miner Res"},{"issue":"6","key":"4984_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1359\/jbmr.1998.13.6.1051","volume":"13","author":"F Cosman","year":"1998","unstructured":"Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13(6):1051\u20131055","journal-title":"J Bone Miner Res"},{"issue":"9","key":"4984_CR11","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"4984_CR12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gl\u00fcer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24(4):726\u2013736","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4984_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.maturitas.2005.08.011","volume":"54","author":"C Garc\u00e9s","year":"2006","unstructured":"Garc\u00e9s C, Garc\u00eda LE (2006) Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Maturitas 54(1):47\u201354","journal-title":"Maturitas"},{"issue":"1","key":"4984_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157(1):141\u2013149","journal-title":"Endocrinology"},{"issue":"5","key":"4984_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/13543776.2019.1608180","volume":"29","author":"SA Holstein","year":"2019","unstructured":"Holstein SA (2019) A patent review of bisphosphonates in treating bone disease. Expert Opin Ther Pat 29(5):315\u2013325","journal-title":"Expert Opin Ther Pat"},{"issue":"1","key":"4984_CR16","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1038\/s41598-021-86468-9","volume":"11","author":"S Jain","year":"2021","unstructured":"Jain S, Rai R, Singh D, Vohora D (2021) Octanoic acid a major component of widely consumed medium-chain triglyceride ketogenic diet is detrimental to bone. Sci Rep 11(1):7003","journal-title":"Sci Rep"},{"issue":"9","key":"4984_CR17","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1210\/en.2007-0229","volume":"148","author":"S Johnston","year":"2007","unstructured":"Johnston S, Andrews S, Shen V, Cosman F, Lindsay R, Dempster DW, Iida-Klein A (2007) The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL\/6J mice. Endocrinology 148(9):4466\u20134474","journal-title":"Endocrinology"},{"issue":"5","key":"4984_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/fcp.12208","volume":"30","author":"A Kalam","year":"2016","unstructured":"Kalam A, Talegaonkar S, Vohora D (2016) Differential profile of letrozole and exemestane on bone turnover markers in vinylcyclohexene diepoxide treated ovotoxic female mice. Fundam Clin Pharmacol 30(5):429\u2013439","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"4984_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/19396368.2011.648820","volume":"58","author":"CJ Kappeler","year":"2012","unstructured":"Kappeler CJ, Hoyer PB (2012) 4-Vinylcyclohexene diepoxide: a model chemical for ovotoxicity. Syst Biol Reprod Med 58(1):57\u201362","journal-title":"Syst Biol Reprod Med"},{"key":"4984_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.msec.2016.10.066","volume":"71","author":"DK Khajuria","year":"2017","unstructured":"Khajuria DK, Vasireddi R, Trebbin M, Karasik D, Razdan R (2017) Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: in vitro and pharmacodynamic evaluation. Mater Sci Eng C Mater Biol Appl 71:698\u2013708","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"4984_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40364-017-0097-4","volume":"5","author":"TR Kuo","year":"2017","unstructured":"Kuo TR, Chen CH (2017) Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res 5:18","journal-title":"Biomark Res"},{"issue":"12","key":"4984_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","volume":"15","author":"ES Kurland","year":"2004","unstructured":"Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 15(12):992\u2013997","journal-title":"Osteoporos Int"},{"issue":"4","key":"4984_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jbmr.3930","volume":"35","author":"C Le Henaff","year":"2020","unstructured":"Le Henaff C, Ricarte F, Finnie B, He Z, Johnson J, Warshaw J, Kolupaeva V, Partridge NC (2020) Abaloparatide at the same dose has the same effects on bone as PTH (1-34) in mice. J Bone Miner Res 35(4):714\u2013724","journal-title":"J Bone Miner Res"},{"issue":"2","key":"4984_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"BZ Leder","year":"2018","unstructured":"Leder BZ (2018) Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR plus 2(2):62\u201368","journal-title":"JBMR plus"},{"issue":"4","key":"4984_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00198-011-1751-6","volume":"23","author":"YF Li","year":"2012","unstructured":"Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1\u201334) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23(4):1463\u20131474","journal-title":"Osteoporos Int"},{"key":"4984_CR26","doi-asserted-by":"publisher","first-page":"115651","DOI":"10.1016\/j.bone.2020.115651","volume":"142","author":"A Makino","year":"2021","unstructured":"Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N (2021) Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: a comparison with teriparatide. Bone 142:115651","journal-title":"Bone"},{"key":"4984_CR27","doi-asserted-by":"publisher","first-page":"107885","DOI":"10.1016\/j.maturitas.2023.107885","volume":"180","author":"P Mashouri","year":"2024","unstructured":"Mashouri P, Saboune J, Pyle WG, Power GA (2024) Effects of chemically induced ovarian failure on single muscle fiber contractility in a mouse model of menopause. Maturitas 180:107885","journal-title":"Maturitas"},{"issue":"4","key":"4984_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s11914-017-0376-x","volume":"15","author":"MR McClung","year":"2017","unstructured":"McClung MR (2017) Using osteoporosis therapies in combination. Curr Osteoporos Rep 15(4):343\u2013352","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"4984_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733","journal-title":"JAMA"},{"issue":"1","key":"4984_CR30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jbmr.1716","volume":"28","author":"C Muschitz","year":"2013","unstructured":"Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H (2013) Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density. J Bone Miner Res 28(1):196\u2013205","journal-title":"J Bone Miner Res"},{"key":"4984_CR31","doi-asserted-by":"publisher","first-page":"944323","DOI":"10.3389\/fendo.2022.944323","volume":"13","author":"N Nirwan","year":"2022","unstructured":"Nirwan N, Vohora D (2022) Linagliptin in combination with metformin ameliorates diabetic osteoporosis through modulating BMP-2 and sclerostin in the high-fat diet fed C57BL\/6 mice. Front Endocrinol (Lausanne) 13:944323","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4984_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejps.2014.09.002","volume":"65","author":"FH Pottoo","year":"2014","unstructured":"Pottoo FH, Bhowmik M, Vohora D (2014) Raloxifene protects against seizures and neurodegeneration in a mouse model mimicking epilepsy in postmenopausal woman. Eur J Pharm Sci 65:167\u2013173","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"4984_CR33","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1530\/JME-18-0173","volume":"62","author":"TD Rachner","year":"2019","unstructured":"Rachner TD, Hofbauer LC, G\u00f6bel A, Tsourdi E (2019) Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. J Mol Endocrinol 62(2):R145-r154","journal-title":"J Mol Endocrinol"},{"key":"4984_CR34","first-page":"154","volume":"34","author":"A Rashki Kemmak","year":"2020","unstructured":"Rashki Kemmak A, Rezapour A, Jahangiri R, Nikjoo S, Farabi H, Soleimanpour S (2020) Economic burden of osteoporosis in the world: a systematic review. Med J Islam Repub Iran 34:154","journal-title":"Med J Islam Repub Iran"},{"key":"4984_CR35","doi-asserted-by":"publisher","first-page":"115390","DOI":"10.1016\/j.bone.2020.115390","volume":"137","author":"IR Reid","year":"2020","unstructured":"Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF (2020) Zoledronate. Bone 137:115390","journal-title":"Bone"},{"issue":"6","key":"4984_CR36","first-page":"2129","volume":"85","author":"RS Rittmaster","year":"2000","unstructured":"Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85(6):2129\u20132134","journal-title":"J Clin Endocrinol Metab"},{"key":"4984_CR37","doi-asserted-by":"publisher","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493","journal-title":"Bone"},{"issue":"19","key":"4984_CR38","doi-asserted-by":"publisher","first-page":"e14225","DOI":"10.14814\/phy2.14225","volume":"7","author":"K Sahbani","year":"2019","unstructured":"Sahbani K, Cardozo CP, Bauman WA, Tawfeek HA (2019) Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and \u03b2-arrestin recruitment than teriparatide. Physiol Rep 7(19):e14225","journal-title":"Physiol Rep"},{"key":"4984_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bonr.2017.06.001","volume":"7","author":"T Shimizu","year":"2017","unstructured":"Shimizu T, Tanaka T, Kobayashi T, Kudo I, Nakatsugawa M, Takakura A, Takao-Kawabata R, Ishizuya T (2017) Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats. Bone Rep 7:70\u201382","journal-title":"Bone Rep"},{"issue":"12","key":"4984_CR40","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-017-0780-7","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M (2017) Abaloparatide: first global approval. Drugs 77(12):1363\u20131368","journal-title":"Drugs"},{"issue":"7","key":"4984_CR41","doi-asserted-by":"publisher","first-page":"e0132104","DOI":"10.1371\/journal.pone.0132104","volume":"10","author":"B Shuai","year":"2015","unstructured":"Shuai B, Shen L, Yang Y, Ma C, Zhu R, Xu X (2015) Assessment of the impact of zoledronic acid on ovariectomized osteoporosis model using micro-CT scanning. PLoS ONE 10(7):e0132104","journal-title":"PLoS ONE"},{"issue":"5","key":"4984_CR42","first-page":"e1300","volume":"9","author":"SH Tella","year":"2017","unstructured":"Tella SH, Kommalapati A, Correa R (2017) Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis. Cureus 9(5):e1300","journal-title":"Cureus"},{"issue":"2","key":"4984_CR43","first-page":"92","volume":"43","author":"KN Tu","year":"2018","unstructured":"Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D (2018) Osteoporosis: a review of treatment options. P T 43(2):92\u2013104","journal-title":"P T"},{"issue":"8","key":"4984_CR44","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, Kanis JA (2011) International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 49(8):1271\u20131274","journal-title":"Clin Chem Lab Med"},{"key":"4984_CR45","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bone.2014.06.020","volume":"66","author":"JB Vegger","year":"2014","unstructured":"Vegger JB, Nielsen ES, Br\u00fcel A, Thomsen JS (2014) Additive effect of PTH (1-34) and zoledronate in the prevention of disuse osteopenia in rats. Bone 66:287\u2013295","journal-title":"Bone"},{"issue":"1","key":"4984_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","volume":"44","author":"MD Walker","year":"2013","unstructured":"Walker MD, Cusano NE, Sliney J Jr., Romano M, Zhang C, McMahon DJ, Bilezikian JP (2013) Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44(1):237\u2013246","journal-title":"Endocrine"},{"key":"4984_CR47","doi-asserted-by":"publisher","first-page":"961941","DOI":"10.3389\/fphar.2022.961941","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Zhan Y, Yan L, Hao D (2022) How zoledronic acid improves osteoporosis by acting on osteoclasts. Front Pharmacol 13:961941","journal-title":"Front Pharmacol"},{"issue":"8","key":"4984_CR48","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1359\/jbmr.080309","volume":"23","author":"LE Wright","year":"2008","unstructured":"Wright LE, Christian PJ, Rivera Z, Van Alstine WG, Funk JL, Bouxsein ML, Hoyer PB (2008) Comparison of skeletal effects of ovariectomy versus chemically induced ovarian failure in mice. J Bone Miner Res 23(8):1296\u20131303","journal-title":"J Bone Miner Res"},{"issue":"1","key":"4984_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41413-024-00356-2","volume":"12","author":"Y Wu","year":"2024","unstructured":"Wu Y, Sun B, Tang Y, Shen A, Lin Y, Zhao X, Li J, Monteiro MJ, Gu W (2024) Bone targeted nano-drug and nano-delivery. Bone Res 12(1):51","journal-title":"Bone Res"},{"issue":"1","key":"4984_CR50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bone.2012.09.039","volume":"52","author":"X Yang","year":"2013","unstructured":"Yang X, Muthukumaran P, DasDe S, Teoh SH, Choi H, Lim SK, Lee T (2013) Positive alterations of viscoelastic and geometric properties in ovariectomized rat femurs with concurrent administration of ibandronate and PTH. Bone 52(1):308\u2013317","journal-title":"Bone"},{"key":"4984_CR51","doi-asserted-by":"publisher","first-page":"607017","DOI":"10.3389\/fphar.2020.607017","volume":"11","author":"C Zhang","year":"2020","unstructured":"Zhang C, Song C (2020) Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives. Front Pharmacol 11:607017","journal-title":"Front Pharmacol"},{"issue":"4","key":"4984_CR52","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.1096\/fj.201801791RR","volume":"33","author":"W Zhu","year":"2019","unstructured":"Zhu W, Xu R, Du J, Fu Y, Li S, Zhang P, Liu L, Jiang H (2019) Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J 33(4):5208\u20135219","journal-title":"FASEB J"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-04984-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-04984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:03:24Z","timestamp":1782101004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-04984-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4984"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-04984-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7657337\/v1","asserted-by":"object"}]},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}